SPRINT — Sprint Bioscience AB Cashflow Statement
0.000.00%
Last trade - 00:00- SEK90.63m
- SEK50.74m
- SEK50.49m
- 62
- 70
- 55
- 69
Annual cashflow statement for Sprint Bioscience AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -20.2 | -37.8 | -25.6 | -60.7 | -0.845 |
| Depreciation | |||||
| Changes in Working Capital | -8.49 | 4.93 | -15.1 | 1.07 | 23.3 |
| Change in Accounts Receivable | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -28 | -32.2 | -40.1 | -59.1 | 22.9 |
| Capital Expenditures | -0.093 | 0 | -2.71 | 0 | -2.45 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0.296 | 0 | — | — | — |
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.389 | 0 | -2.71 | 0 | -2.45 |
| Financing Cash Flow Items | -2.16 | -8.02 | -12.4 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 22.1 | 50.9 | 86.4 | 17.9 | 0.024 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -6.31 | 18.7 | 43.6 | -41.2 | 20.4 |